Half-year report · Q2
4323.TEDINET S100UP5I
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥26.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥1.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥672m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥651m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥677m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥649m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥20.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥20.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥18.5bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥7.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥13.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥12.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥588m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥929m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥433m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥761m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥220m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥588m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥424m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥409m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥27.38 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.08 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.55 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥48m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥48m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥977m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥24m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥51m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥104,000 |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥77m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥641m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥48m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥34m |
| jpcrp040300-q2r_E05236-000Global Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥204m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥917m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥917m |
| jpcrp040300-q2r_E05236-000Medical Big Data Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥104m |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥407,000 |
| jpcrp040300-q2r_E05236-000Package Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥601m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥2.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 541
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 319933000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -384263000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 6793050000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 7515186000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 7112983000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 7130923000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 782235000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 897453000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 199696000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 200688000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 44652000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 62957000 | JPY |
| Directors share based compensation expenses sga | Prior1YTDDuration | 7945000 | JPY |
| Directors share based compensation expenses sga | CurrentYTDDuration | 5240000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | － | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 400000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 31028000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 28130000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 120912000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 137080000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 7299159000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2255060000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | 917161000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 1661199000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 12132581000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 12132581000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 54142000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 407000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 34317000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 88867000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -88867000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 7353302000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2255468000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | 917161000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 1695517000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 12221449000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -88867000 | JPY |
| Net sales | Prior1YTDDuration | 12132581000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 1150438000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 601490000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05236-000MedicalBigDataBusinessReportableSegmentMember | 103986000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05236-000GlobalBusinessReportableSegmentMember | 204206000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2060122000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -1056556000 | JPY |
| Operating income | Prior1YTDDuration | 1003566000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05236-000DXAndSIBusinessMember | 8239108000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05236-000PackageBusinessReportableSegmentMember | 2567198000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |